New first-in-human study explores immune-engineered cell therapy approach for type 1 diabetes
Researchers have launched a first-in-human study to test if immune-engineered, insulin-producing cells can function in type 1 diabetes patients without the need for chronic immunosuppression. This approach aims to overcome the primary barrier of immune rejection in cell replacement therapies.
Why it matters
If successful, this therapy could provide a curative treatment for type 1 diabetes, significantly improving patient quality of life by eliminating the need for long-term immunosuppressive drugs.
by International Society for Stem Cell Research
edited by Sadie Harley , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Unsplash/CC0 Public Domain New research presented at the International Society for Stem Cell Research ( ISSCR ) 2026 Annual Meeting explores an approach that could expand the potential of cell replacement therapy for type 1 diabetes by evaluating whether immune-engineered, allogeneic insulin-producing cells can survive and function without chronic immunosuppression.
The study addresses one of the field's central challenges: overcoming immune rejection , which has limited the broader use of islet and stem cell-based replacement therapies for type 1 diabetes.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in